PF-05089771: Clinical Trials

14 completed. 10 Phase 1, 3 Phase 2, 1 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 1	10	Completed 10
Phase 2	3	Completed 3
Early Phase 1	1	Completed 1

Follow PF-05089771: new trials by email Literature Review of PF-05089771 trials Research Report on PF-05089771

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8 Room temperature, Cold temperature, Lidocain - Pain	Early Phase 1	Completed	Medical University of Vienna	36	2023-07-07	2024-03-15
Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints PF-05089771 300mg, PF-05089771 300 mg + pregabalin 300 mg, Placebo - Healthy	Phase 1	Completed	Pfizer	25	2015-01-01	2015-04-23
A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN) PF-05089771 150 mg, Matched placebo for PF-05089771 150 mg and pregabalin 300 mg, Pregabalin 300 mg - Diabetic Neuropathy, Painful	Phase 2	Completed	Pfizer	141	2014-11-10	2017-05-05
Drug-Drug Interaction Study With PF-05089771 Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771 - Healthy	Phase 1	Completed	Pfizer	17	2013-09-01	2014-01-16
Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion PF-05089771 - Healthy	Phase 1	Completed	Pfizer	12	2013-05-01	2013-06-25
Safety And Tolerability Study Of BID Titration Scheme With PF-05089771 PF-05089771, Placebo - Healthy	Phase 1	Completed	Pfizer	40	2013-01-01	2013-05-10
Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia PF-05089771, Placebo - Inherited Erythromelalgia	Phase 2	Completed	Pfizer	5	2012-10-22	2019-11-19
A Study Comparing PF-05089771 TS Capsule To PF-05089771 TS Oral Dispersion In The Fasted State PF-05089771 - Pain	Phase 1	Completed	Pfizer	12	2012-09-01	2012-12-12
A Study Comparing PF-05089771 TS Tablet to PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And Fed State PF-05089771 - Pain	Phase 1	Completed	Pfizer	12	2012-02-01	2012-03-27
A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee PF-05089771 - Pain	Phase 1	Completed	Pfizer	80	2012-01-01	2012-12-12
Efficacy Of PF-05089771 In Treating Postoperative Dental Pain PF-05089771, Placebo, Ibuprofen - Postoperative Dental Pain	Phase 2	Completed	Pfizer	235	2011-12-12	2018-06-01
The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period. PF-05089771 - Pain	Phase 1	Completed	Pfizer	30	2011-06-01	2011-10-06
A Single Dose Escalation Study In Healthy Volunteers To Determine The Pharmacokinetics, Safety And Tolerability Of PF-05089771 In Healthy Volunteers PF-05089771 - Pain	Phase 1	Completed	Pfizer	61	2010-12-01	2012-02-02
To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity PF-05186462, PF-05089771, PF-05150122 - Healthy	Phase 1	Completed	Pfizer	40	2010-07-01	2010-08-24

Conditions studied

Pain (6)  ·  Chronic Pain (1)  ·  Diabetic Neuropathies (1)

Sponsors

Pfizer (13)  ·  Medical University of Vienna (1)

Countries

Belgium (7)  ·  United States (4)  ·  Austria (1)  ·  Netherlands (1)  ·  United Kingdom (1)

Top investigators

Michael JM Fischer (1)

Results publications

PMID 27099175, PMID 39693244

NIH funding

2014 (1)